Autres langues Heartseed Inc.

Actions

219A

JP3765140003

Recherche biotechnologique et médicale

Marché Fermé - Japan Exchange Autres places de cotation 08:30:00 17/04/2026			Varia. 5j.	Varia. 1 janv.
1 925,00 ^JPY	-0,47 %		+0,10 %	+6,71 %

25/02	Heartseed Inc. annonce la retraite de Mutsuki Takano en tant qu'administrateur, à compter du 27 mars 2026	CI
13/02	Heartseed Inc. publie ses prévisions de résultats non consolidés pour l'exercice clos le 31 décembre 2026	CI

Autres langues

25/02	Heartseed Inc. Announces Retirement of Mutsuki Takano as Director, Effective March 27, 2026
13/02	Heartseed Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2026
11/12	Heartseed Inc. Revises Earnings Guidance for the Fiscal Year Ending December 31, 2025
04/11	Heartseed Inc. Announces Completion of 30-Day Review for Clinical Trial Notification for Phase I/II Study of HS-005
02/10/25	Heartseed Files Clinical Trial Notification for Heart Failure Therapy HS-005
02/10/25	Heartseed Inc. Completes the Submission of a Clinical Trial Notification to the Pharmaceuticals and Medical Devices Agency Regarding the Commencement of the Japan Clinical Trial for HS-005
30/09/25	Japanese Shares Decline As BOJ Minutes Hint At Tightening Path
30/09/25	Heartseed Says Novo Nordisk Ends Partnership on Heart Cell Therapy
30/09/25	Heartseed Inc - Notice regarding termination of partnership with Novo Nordisk AS
30/09/25	Heartseed Inc. Announces Termination of Partnership with Novo Nordisk A/S
22/09/25	Heartseed Inc.(TSE:219A) added to S&P Global BMI Index
11/09/25	Heartseed, Japan Lifeline Partner on Catheter Delivery for iPS Cell Heart Therapy
11/09/25	Heartseed Inc. and Japan Lifeline Co., Ltd. Announces the Collaboration and Partnership Regarding the Clinical Trial of Heartseed's Allogeneic Ips Cell-Derived Cardiomyocyte Spheroids "Hs-005"
14/08/25	Heartseed Inc. Revises Earnings Guidance for the Fiscal Year Ending December 31, 2025
12/06/25	Heartseed Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2025
13/03/25	Heartseed Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2025
03/02/25	Heartseed Announces Enrollment Completion in Phase 1/2 Clinical Trial Using HS-001, an Investigational Stem Cell-Derived Therapy for Advanced Heart Failure
25/01/25	Certain Common Stock of Heartseed Inc. are subject to a Lock-Up Agreement Ending on 25-JAN-2025.
13/12/24	Heartseed Inc. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2025
12/12/24	Heartseed Doses Nine Patients in LAPiS Clinical Trial
12/12/24	Heartseed Inc. Announces Progress of Phase 1/2 Clinical Trial (LAPiS Study)
17/10/24	Heartseed Boosts Full-Year Forecast Following Early Milestone Achievement with Novo Nordisk Deal
16/10/24	Heartseed Inc. Revises Earnings Guidance for the Fiscal Year Ending October 31, 2024
13/09/24	Heartseed Inc. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2024
31/07/24	Heartseed Advances HS-001 to High-Dose Phase After Positive Safety Review